Industry Briefs: July 16, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
DSM Pharmaceutical Products has signed a biologics contract manufacturing agreement with Recepta Biopharma, based in Brazil. The contract covers the process development and cGMP manufacture by DSM of one of Recepta’s lead antibodies at DSM’s facilities in Groningen, the Netherlands. Read More
Verastem has formed a research collaboration with Eisai for small-molecule Wnt inhibitors. Read More
People News
AstraZeneca has reported on the terms of David Brennan’s retirement. As previously announced, Brennan relinquished his responsibilities as CEO and executive director on June 1, 2012. Brennan received a lump sum payment of £914,122 ($1.43 million) in lieu of contractual notice, representing 11 months’ base pay. Read More
Pharmaceutical Product Development has named Louis Renzetti vice-president of strategic laboratory operations. Read More
Pharmanet/I3 has appointed Robert Lasser as vice-president and general manager of neuroscience. Read More
